Starting a peptide protocol for the first time involves several decisions that are easier to make with a framework than by guessing. Which compound to begin with, what dose to start at, how often to administer it, what to track, and how long to run it before assessing. These are the practical questions that determine whether a first protocol produces useful data or confusion.
This guide is a structural framework. It covers the sequence of decisions involved in setting up and running a first protocol, with enough context at each step to make an informed choice. It is organized around the assumption that the reader is genuinely new to peptide use, not someone optimizing an existing stack, but someone preparing to run their first compound.
Before you start
Before administering anything, there are a few prerequisites that make the difference between a protocol you can learn from and one that generates ambiguous results.
Have your supplies ready
Running out of supplies mid-protocol, or realizing you forgot bacteriostatic water, creates unnecessary gaps. For injectable peptides, the supply list includes:
- The compound itself: for research peptides, lyophilized (freeze-dried) powder in a sealed vial. The FDA warns that products sold "for research purposes" are of unknown quality.20
- Bacteriostatic water (BAC water): for reconstitution. It contains benzyl alcohol as a preservative and is made for repeated withdrawals; plain sterile water has no preservative and is single-dose.1011
- Insulin syringes: U-100 (100 units per mL), 0.5ml or 1ml, for SubQ injection, enough for the whole protocol plus spares.12
- Alcohol swabs: for vial septum and injection site preparation
- Sharps container: for safe needle disposal
If you have not reconstituted a peptide before, the reconstitution guide walks through the process step by step, and the reconstitution calculator handles the math for any vial size and target dose.
Bloodwork before starting gives reference values for the person, so later results can be read as changes rather than impressions. The bloodwork timing guide covers which panels fit which compounds.
Choosing your first compound
Common advice in peptide communities is to start with one compound, not a stack. If something changes after starting, positive or negative, a single compound means the cause is known.
The compound follows the goal. Common starting points by use case, with the state of the evidence for each:
Healing and recovery
BPC-157 is a common first peptide for healing and recovery. It is described as a naturally occurring gastric peptide; of 36 studies in a 2025 systematic review, 35 were preclinical and 1 clinical, with no clinical safety data.2 Its half-life was under 30 minutes in rats and dogs, and it is usually dosed daily.3 It is not approved, and the FDA notes limited safety information.1
Weight management
Semaglutide and tirzepatide are the main weight management compounds, both approved. Semaglutide is a GLP-1 receptor agonist with a half-life of approximately 1 week; tirzepatide is a GIP and GLP-1 receptor agonist with a half-life of approximately 5 days; both are dosed weekly with a titration schedule.4567
Growth hormone optimization
Ipamorelin and CJC-1295 (no DAC) are common first GH secretagogues. Ipamorelin releases GH through a GHRP-like receptor and, in swine, did not raise ACTH or cortisol.8 CJC-1295 is a GHRH analogue; its published trial tested the long-acting form.9 Neither is approved.1
It is tempting to start with a stack, such as BPC-157 with TB-500, or CJC-1295 with ipamorelin. As a first protocol, a stack makes it impossible to tell which compound is doing what, positive or negative.
Setting up your protocol
A protocol has four core parameters: dose, frequency, route, and timing. For the approved drugs, the label sets them. For research peptides, no label or human dose trial exists, so this page gives no dose.1
| Compound | Starting dose | Frequency | Route | Typical duration |
|---|---|---|---|---|
| BPC-157 | No label or human dose trial | Daily (community) | SubQ | Community courses vary |
| TB-500 | No human exposure data1 | Varies (community) | SubQ | Community courses vary |
| Semaglutide | 0.25 mg (Wegovy)6 | Weekly | SubQ | Ongoing; titrates every 4 weeks |
| Tirzepatide | 2.5 mg (Zepbound)7 | Weekly | SubQ | Ongoing; steps of 2.5 mg, at least 4 weeks apart |
| Ipamorelin | No label | 1-3x daily (community) | SubQ | Community courses vary |
| CJC-1295 (no DAC) | No label | 1-3x daily (community) | SubQ | Community courses vary |
Timing varies. Wegovy is given once weekly on the same day each week, at any time of day, with or without meals.6 BPC-157 is often injected in the morning or split morning and evening. GH secretagogues are often dosed before bed or on waking on an empty stomach; no trial of timing was found.
Route for most injectable peptides is subcutaneous; the GLP-1 labels are for subcutaneous use in the abdomen, thigh or upper arm.6 The injection technique guide covers sites, rotation and technique.
The first two weeks
The first two weeks are an adjustment period. Levels are building toward steady state, which takes about 5 half-lives of consistent dosing.16 Knowing what to expect in this window prevents early disappointment.
What is normal
- Injection site reactions: minor redness, small bumps and occasional bruising are listed among injection site reactions on the Zepbound label (6-8% against 2% on placebo).7
- GLP-1 GI effects: nausea, reduced appetite and constipation are common during titration; in STEP 1 they were typically transient and mild to moderate and subsided with time, and in SURMOUNT-1 they occurred primarily during dose escalation.1314
- GH secretagogue effects: mild water retention, more hunger and better sleep are commonly reported. In a 2-year MK-677 trial, increased appetite and mild lower-leg edema were the most frequent side effects.19
- Healing peptides: no human timeline exists for BPC-157 or TB-500; the research is mostly preclinical.2
What is not normal
Persistent redness, swelling or warmth at an injection site that worsens over a day or two rather than improving, fever, or significant unexpected symptoms are not the typical pattern and are for professional evaluation.
Setting realistic expectations
A common frustration in the first two weeks is expecting visible results too soon. Even GLP-1 agonists start at low doses: Wegovy begins at 0.25 mg and reaches its maintenance dose from week 17.6
Pharmacokinetically, a compound reaches steady state after about 5 half-lives of consistent dosing.16 On BPC-157's animal half-life of under 30 minutes, that is within hours.3 Semaglutide, with a half-life of approximately 1 week, reaches steady state after 4 to 5 weeks of weekly doses.4
Tracking your progress
Tracking turns "I think something is happening" into "I can see what is happening". Without data, the only tools are memory and impression, both biased toward recent days and by expectation.
Daily subjective check-ins
A brief daily check-in covering key subjective markers creates a dataset that reveals trends invisible to day-to-day perception. Common markers to track:
- Energy: overall energy level on a 1-5 scale
- Sleep quality: how rested you feel, independent of hours slept
- Mood: baseline emotional state
- Recovery: how recovered you feel from physical activity
- Appetite: particularly relevant for GLP-1 protocols
- Compound-specific markers: soreness for healing protocols, skin quality for GHK-Cu, etc.
A check-in takes under a minute. The value builds over weeks: a trend line showing energy improving or sleep settling is evidence that something is changing, or that it is not, which is also useful.
Measurements and photos
For body composition goals, periodic measurements add objective data: weight (same time, same conditions), waist circumference, and standard progress photos every 2-4 weeks. The scale alone is not enough, because day-to-day water shifts move it.
Bloodwork scheduling
Baseline bloodwork and a follow-up once levels reach steady state give the most useful comparison. The markers depend on the compound; the bloodwork timing guide covers which panels fit each category.
When to adjust
A common first-protocol mistake is changing too early. Changing dose or frequency, or dropping a compound, before steady state and before effects have had time leads to unclear results. When the evidence suggests looking:
- Healing peptides (BPC-157, TB-500): no human timeline exists to assess against; community reports range from 2 to 6 weeks.2
- GLP-1 agonists (semaglutide, tirzepatide): the titration schedule is the framework: each dose is held at least 4 weeks before the next step, by the labels.67
- GH secretagogues (Ipamorelin, CJC-1295): IGF-1 bloodwork gives objective data on GH axis stimulation; a review describes IGF-1 as a stable indication of integrated GH secretion.17 No trial of these peptides measured body composition over time.
Signs a protocol is working
For most compounds, the signal is gradual: slightly better sleep over a week, a nagging injury feeling a little better, noticing lunch was forgotten. Dramatic overnight changes are not the usual pattern.
Signs to reconsider
If a compound has been run consistently for a reasonable period with no subjective or objective change, that is information. Possible explanations include product quality, dose, or individual non-response. Any change of dose or compound is a decision for the person and their clinician.
Common beginner mistakes
Starting multiple compounds at once
Stacking from day one makes attribution impossible. With BPC-157, TB-500 and ipamorelin started together, feeling better in week 3 says nothing about which compound did it, or whether all three are needed.
Inconsistent dosing
Pharmacokinetic models assume consistent dosing intervals. Missed or irregular doses give irregular levels and harder-to-read results. Same time each day, or same day each week, keeps levels steady.
Not tracking anything
A protocol without tracking is an experiment without a record. A short daily check-in on a few markers, plus periodic measurements, turns impressions into something that can be looked back on.
Unrealistic timelines
Expecting visible results in 3 days from a healing peptide, or large weight loss in the first week of semaglutide at 0.25 mg, the label's starting dose, sets up disappointment. The semaglutide trial endpoint was at 68 weeks.613
Poor reconstitution and storage
Reconstituting with plain sterile water (no preservative, single-dose only), storing at room temperature, shaking, or using a vial past its limit can all affect what each dose delivers.11 Approved reconstituted products are refrigerated and used within set limits, such as 28 days for Humatrope.18 The storage guide covers this.
Frequently asked questions
How long should a first peptide protocol be?
For research peptides, course lengths come from community practice, not trials, often 4 to 12 weeks.2 GLP-1 agonists like semaglutide are used continuously in their trials and labels.136
When should I expect to see results from peptides?
It varies by compound. The GLP-1 trials measured weight at 68 to 72 weeks after titration.1314 For testosterone, a review found effects from week 3 for some measures and 12-16 weeks for body composition.15 For research peptides such as BPC-157, no human timeline was found.2
Can I stack multiple peptides on my first protocol?
Starting with one compound is common advice: it gives a clear baseline, so any change has a known source. Some combinations, such as CJC-1295 with ipamorelin, are usually started together; for a first protocol, one compound keeps attribution clear.
What happens if I miss a peptide dose?
For the approved weekly drugs, the labels say what to do. Wegovy: if the next dose is more than 2 days away, take the missed dose as soon as possible. Zepbound: take it within 4 days (96 hours), or skip it and take the next dose on the usual day; do not take two doses together.67 For research peptides no label exists.
When should I get bloodwork on a peptide protocol?
Baseline bloodwork gives reference values for the person, and a follow-up once levels are steady shows the change. The markers depend on the compound: glucose, HbA1c and lipids for GLP-1 protocols, and IGF-1 and fasting glucose for GH secretagogues, where IGF-1 is the stable marker of GH secretion.17
References
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026). 2026. fda.gov
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. pubmed.ncbi.nlm.nih.gov
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs. Front Pharmacol. 2022. pubmed.ncbi.nlm.nih.gov
- Novo Nordisk (DailyMed). Ozempic (semaglutide) injection label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Mounjaro (tirzepatide) injection label. 2026. dailymed.nlm.nih.gov
- Novo Nordisk (DailyMed). Wegovy (semaglutide) label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Zepbound (tirzepatide) label. 2026. dailymed.nlm.nih.gov
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov
- Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov
- Henry Schein (DailyMed). Bacteriostatic Water for Injection, USP, multiple-dose vial label. 2026. dailymed.nlm.nih.gov
- Henry Schein (DailyMed). Sterile Water for Injection, USP, single-dose vial label. 2026. dailymed.nlm.nih.gov
- Eli Lilly (DailyMed). Humulin R (insulin human) injection U-100 label. 2026. dailymed.nlm.nih.gov
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. pubmed.ncbi.nlm.nih.gov
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. pubmed.ncbi.nlm.nih.gov
- Saad F et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011. pubmed.ncbi.nlm.nih.gov
- Hallare J, Gerriets V. Elimination half-life of drugs. StatPearls (NCBI Bookshelf, PubMed record). 2025. pubmed.ncbi.nlm.nih.gov
- Cardoso LM et al. Acromegaly: biochemical diagnosis. Vitam Horm. 2026. pubmed.ncbi.nlm.nih.gov
- Eli Lilly (DailyMed). Humatrope (somatropin) label. 2026. dailymed.nlm.nih.gov
- Nass R et al. Effects of an oral ghrelin mimetic (MK-677) on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008. pubmed.ncbi.nlm.nih.gov
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of 1 October 2026). 2026. fda.gov